Salarius Pharmaceuticals

Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment options. Salarius product portfolio includes seclidemstat, a reversible LSD1 inhibitor, which is being studied as a potential treatment for pediatric cancers, sarcomas, and other cancers with limited treatment options, and SP-3164, an oral small molecule targeted protein degrader. Seclidemstat is currently in a Phase 1/2 clinical trial for relapsed/refractory Ewing sarcoma and select additional sarcomas that share a similar biology to Ewing sarcoma, also referred to as Ewing-related or FET-rearranged sarcomas. Seclidemstat has received Fast Track Designation, Orphan Drug Designation, and Rare...

Childhood cancer,oncology,cancer,epigenetics,and solid tumors

Salarius pharmaceuticals operates in the Pharmaceutical manufacturing industry.

Salarius pharmaceuticals's revenue is 11m - 100m

Salarius pharmaceuticals has 11 - 50 employees.